CA2798431C - Monitoring health and disease status using clonotype profiles - Google Patents

Monitoring health and disease status using clonotype profiles Download PDF

Info

Publication number
CA2798431C
CA2798431C CA2798431A CA2798431A CA2798431C CA 2798431 C CA2798431 C CA 2798431C CA 2798431 A CA2798431 A CA 2798431A CA 2798431 A CA2798431 A CA 2798431A CA 2798431 C CA2798431 C CA 2798431C
Authority
CA
Canada
Prior art keywords
disease
patient
lymphoid neoplasms
patients
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2798431A
Other languages
English (en)
French (fr)
Other versions
CA2798431A1 (en
Inventor
Malek Faham
Thomas Willis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adaptive Biotechnologies Corp
Original Assignee
Adaptive Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2798431(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adaptive Biotechnologies Corp filed Critical Adaptive Biotechnologies Corp
Publication of CA2798431A1 publication Critical patent/CA2798431A1/en
Application granted granted Critical
Publication of CA2798431C publication Critical patent/CA2798431C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CA2798431A 2010-05-06 2011-05-04 Monitoring health and disease status using clonotype profiles Active CA2798431C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33217510P 2010-05-06 2010-05-06
US61/332,175 2010-05-06
US45574310P 2010-10-25 2010-10-25
US61/455,743 2010-10-25
US201161446822P 2011-02-25 2011-02-25
US61/446,822 2011-02-25
PCT/US2011/000791 WO2011139371A1 (en) 2010-05-06 2011-05-04 Monitoring health and disease status using clonotype profiles

Publications (2)

Publication Number Publication Date
CA2798431A1 CA2798431A1 (en) 2011-11-10
CA2798431C true CA2798431C (en) 2018-10-23

Family

ID=44903937

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2798431A Active CA2798431C (en) 2010-05-06 2011-05-04 Monitoring health and disease status using clonotype profiles

Country Status (9)

Country Link
EP (4) EP2567226B1 (enExample)
JP (4) JP6158080B2 (enExample)
CN (2) CN103097888B (enExample)
AU (1) AU2011249041B2 (enExample)
CA (1) CA2798431C (enExample)
DK (2) DK3144673T3 (enExample)
ES (2) ES2593614T3 (enExample)
SG (2) SG10201503534RA (enExample)
WO (2) WO2011139372A1 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
EP2364368B1 (en) * 2008-11-07 2014-01-15 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US9394567B2 (en) 2008-11-07 2016-07-19 Adaptive Biotechnologies Corporation Detection and quantification of sample contamination in immune repertoire analysis
US8691510B2 (en) 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
DK3059337T3 (da) 2009-01-15 2019-07-22 Adaptive Biotechnologies Corp Adaptive immunity profiling og metoder til frembringelse af monoklonale antibodier
RU2014144463A (ru) 2009-06-25 2015-06-20 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения адаптивного иммунитета
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
ES2615733T3 (es) 2010-12-16 2017-06-08 Gigagen, Inc. Métodos para el análisis masivo paralelo de ácidos nucleicos en células individuales
KR20140024270A (ko) 2010-12-30 2014-02-28 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
JP2014503223A (ja) * 2011-01-14 2014-02-13 シービー バイオテクノロジーズ インコーポレイテッド 免疫多様性の評価方法およびその使用
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
US9279159B2 (en) 2011-10-21 2016-03-08 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
EP3388535B1 (en) * 2011-12-09 2021-03-24 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
US20140349883A1 (en) * 2011-12-20 2014-11-27 Sequenta, Inc. Monitoring transformation of follicular lymphoma to diffuse large b-cell lymphoma by immune repertoire analysis
DK2823060T3 (en) * 2012-03-05 2018-05-28 Adaptive Biotechnologies Corp Determination of associated immune receptor chains from frequency-matched subunits
JP2015512655A (ja) * 2012-04-13 2015-04-30 シーケンタ インコーポレイテッド 免疫レパートリ分析におけるサンプル混入の検出および定量化
EP3091089B1 (en) 2012-05-08 2019-01-23 Adaptive Biotechnologies Corporation Method for measuring and calibrating amplification bias in multiplexed pcr reactions
WO2013181428A2 (en) * 2012-05-31 2013-12-05 Sequenta, Inc. Predicting relapse of chronic lymphocytic leukemia patients treated by allogeneic stem cell transplantation
AU2013273987B2 (en) * 2012-06-15 2018-08-09 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
US20160115532A1 (en) * 2012-08-10 2016-04-28 Sequenta, Inc. High sensitivity mutation detection using sequence tags
US20160002731A1 (en) 2012-10-01 2016-01-07 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
US10150996B2 (en) 2012-10-19 2018-12-11 Adaptive Biotechnologies Corp. Quantification of adaptive immune cell genomes in a complex mixture of cells
EP2909344A4 (en) * 2012-10-19 2016-06-29 Adaptive Biotechnologies Corp SURVEILLANCE OF CLONOTYPES IN PROLIFERATIVE DISORDERS OF PLASMOCYTES IN PERIPHERAL BLOOD
CA2888524A1 (en) * 2012-10-22 2014-05-01 Sequenta, Inc. Monitoring mantle cell lymphoma clonotypes in peripheral blood after immunotransplant
CN105164277B (zh) * 2013-02-11 2021-05-28 Cb生物技术公司 用于评估免疫组库的方法
JP6513035B2 (ja) * 2013-02-22 2019-05-15 アダプティヴ バイオテクノロジーズ コーポレーション 希少クロノタイプおよびその用途
WO2014145992A1 (en) * 2013-03-15 2014-09-18 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
WO2014144495A1 (en) 2013-03-15 2014-09-18 Abvitro, Inc. Single cell bar-coding for antibody discovery
US9708657B2 (en) * 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
JP6164759B2 (ja) * 2013-11-21 2017-07-19 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用
WO2015134787A2 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
US10202640B2 (en) 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing
KR102541849B1 (ko) 2014-09-15 2023-06-09 에이비비트로, 엘엘씨 고-처리량 뉴클레오티드 라이브러리 서열결정
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
EP3224384A4 (en) 2014-11-25 2018-04-18 Adaptive Biotechnologies Corp. Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
CA2967447C (en) * 2014-12-05 2025-07-08 Foundation Medicine, Inc. MULTIGEN ANALYSIS OF TUMOR SAMPLES
US11047008B2 (en) 2015-02-24 2021-06-29 Adaptive Biotechnologies Corporation Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing
WO2016161273A1 (en) 2015-04-01 2016-10-06 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
CN106557536B (zh) * 2015-09-30 2021-12-21 松下知识产权经营株式会社 控制方法
US10130658B2 (en) * 2015-12-18 2018-11-20 Provectus Pharmatech, Inc. Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
CN107955831A (zh) * 2016-10-13 2018-04-24 深圳华大基因研究院 用于淋巴细胞定量检测的标记物和淋巴细胞定量检测方法
GB201618485D0 (en) * 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
EP3552126B1 (en) * 2016-12-09 2025-05-14 Regeneron Pharmaceuticals, Inc. Systems and methods for sequencing t cell receptors and uses thereof
RU2674994C2 (ru) * 2016-12-29 2018-12-14 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ определения маркеров наличия опухолевых т-лимфобластов
WO2019046817A1 (en) 2017-09-01 2019-03-07 Life Technologies Corporation COMPOSITIONS AND METHODS FOR IMMUNOLOGICAL REPERTOIRE SEQUENCING
CN111479830A (zh) * 2017-10-10 2020-07-31 国立大学法人广岛大学 使用铂talen的t细胞受体的完全取代技术
EP3702454A4 (en) 2017-10-10 2021-08-04 Hiroshima University METHOD FOR GENERATING ANTIGEN-SPECIFIC REGULATORY T-CELLS (TREG) WITH EFFECTOR T-CELL (TEFF) ANTIGEN RECEPTORS
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
US12584163B2 (en) 2018-06-11 2026-03-24 Foundation Medicine, Inc. Compositions and methods for evaluating genomic alterations
US11603565B2 (en) * 2018-06-15 2023-03-14 Roche Sequencing Solutions, Inc. System for identification of antigens recognized by T cell receptors expressed on tumor infiltrating lymphocytes
EP3824103A1 (en) 2018-07-18 2021-05-26 Life Technologies Corporation Compositions and methods for immune repertoire sequencing
CN109002689B (zh) * 2018-07-23 2020-10-09 西安交通大学医学院第一附属医院 T细胞数据处理方法及装置
WO2020102721A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Immune monitoring of neuro-inflammatory amyotrophic lateral sclerosis (als)
JP7614647B2 (ja) * 2018-12-20 2025-01-16 ザ・ジョンズ・ホプキンス・ユニバーシティ １型糖尿病、その他の自己免疫疾患の処置
WO2020191365A1 (en) 2019-03-21 2020-09-24 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
CN110988364A (zh) * 2019-12-31 2020-04-10 天津美瑞特医疗科技有限公司 一种应用流式细胞术检测移植后gvhd相关细胞因子的方法及检测试剂盒
KR20220130756A (ko) * 2020-01-22 2022-09-27 라이프 테크놀로지스 코포레이션 자가면역 질환과 면역결핍 장애의 면역 레퍼토리 바이오마커
CN111808195A (zh) * 2020-06-30 2020-10-23 中国科学院心理研究所 抗n-甲基-d-天冬氨酸受体脑炎的b细胞抗体基因获取方法及其免疫组库研究
CN111524548B (zh) * 2020-07-03 2020-10-23 至本医疗科技（上海）有限公司 用于检测igh重排的方法、计算设备和计算机存储介质
CA3214486A1 (en) 2021-03-24 2022-09-29 Genentech, Inc. Efficient tcr gene editing in t lymphocytes
CN113637741B (zh) * 2021-09-29 2023-12-01 成都二十三魔方生物科技有限公司 一种早发性白发遗传风险基因检测试剂盒、以及一种早发性白发遗传风险评估系统和方法
EP4726393A1 (en) * 2023-06-12 2026-04-15 National University Corporation Kobe University Immune reaction evaluation method
WO2025122939A1 (en) * 2023-12-08 2025-06-12 Dana-Farber Cancer Institute, Inc. Detection and classification of b-cell malignancies
CN117867121A (zh) * 2024-01-12 2024-04-12 广州华银医学检验中心有限公司 一种检测肿瘤免疫组库微小残留的引物组合和方法
WO2025243303A1 (en) * 2024-05-22 2025-11-27 Technion Research & Development Foundation Limited Improved methods of determining immune age
CN120432008B (zh) * 2025-05-07 2026-02-06 博德生物技术（德州）有限公司 CellRanger单细胞RNA测序数据分析方法
CN120290752B (zh) * 2025-06-13 2025-09-16 北京大学成都前沿交叉生物技术研究院 捕获探针、包含其的试剂盒及利用其在空间分辨率下检测t细胞和b细胞免疫组库中的用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4942124A (en) 1987-08-11 1990-07-17 President And Fellows Of Harvard College Multiplex sequencing
US5168038A (en) 1988-06-17 1992-12-01 The Board Of Trustees Of The Leland Stanford Junior University In situ transcription in cells and tissues
US5296351A (en) 1988-10-20 1994-03-22 Alexander A. Morley Method for diagnosis of monoclonality in leukaemia and lymphoma
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
JP3080178B2 (ja) 1991-02-18 2000-08-21 東洋紡績株式会社 核酸配列の増幅方法およびそのための試薬キット
US5981179A (en) 1991-11-14 1999-11-09 Digene Diagnostics, Inc. Continuous amplification reaction
US5837447A (en) 1992-04-15 1998-11-17 Blood Center Research Foundation, Inc., The Monitoring an immune response by analysis of amplified immunoglobulin or T-cell-receptor nucleic acid
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US6090592A (en) 1994-08-03 2000-07-18 Mosaic Technologies, Inc. Method for performing amplification of nucleic acid on supports
US5604097A (en) 1994-10-13 1997-02-18 Spectragen, Inc. Methods for sorting polynucleotides using oligonucleotide tags
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US6087096A (en) 1995-11-13 2000-07-11 Dau; Peter C. Method of intrafamily fragment analysis of the T cell receptor α and β chain CDR3 regions
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US20020076725A1 (en) * 1996-03-13 2002-06-20 Tomoko Toyosaki-Maeda Human t cell clone specific for rheumatoid arthritis
US6458530B1 (en) 1996-04-04 2002-10-01 Affymetrix Inc. Selecting tag nucleic acids
EP0910668A4 (en) * 1996-06-03 2003-02-19 Univ Alberta METHOD FOR DETECTING REASSEMBLED DNA
ATE428801T1 (de) 1996-06-04 2009-05-15 Univ Utah Res Found Überwachung der hybridisierung während pcr
US5846928A (en) 1996-08-01 1998-12-08 Pasken Products Co., Ltd. Method for treating cancer patients
EP0937251B1 (en) 1996-09-06 2006-11-29 Ortho-McNeil Pharmaceutical, Inc. Purification of antigen-specific t cells
GB9626815D0 (en) * 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
EP1591541B1 (en) 1997-04-01 2012-02-15 Illumina Cambridge Limited Method of nucleic acid sequencing
US6008002A (en) 1997-09-29 1999-12-28 Bodey; Bela Immunomagnetic detection and isolation of cancer cells
DE69941689D1 (de) 1998-02-12 2010-01-07 Univ Texas Verfahren und reagenzien zur raschen und effizienten isolierung zirkulierender krebszellen
DE19833738A1 (de) 1998-07-27 2000-02-03 Michael Giesing Verfahren zur Isolierung von Krebszellen aus zellhaltigen Körperflüssigkeiten sowie Sets zur Durchführung dieses Verfahrens
AR021833A1 (es) 1998-09-30 2002-08-07 Applied Research Systems Metodos de amplificacion y secuenciacion de acido nucleico
US6300070B1 (en) 1999-06-04 2001-10-09 Mosaic Technologies, Inc. Solid phase methods for amplifying multiple nucleic acids
US6440706B1 (en) 1999-08-02 2002-08-27 Johns Hopkins University Digital amplification
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
GB0128153D0 (en) 2001-11-23 2002-01-16 Bayer Ag Profiling of the immune gene repertoire
EP1549764B1 (en) 2002-10-11 2010-10-06 Erasmus Universiteit Rotterdam Nucleic acid amplification primers for pcr-based clonality studies
CA2513889A1 (en) 2003-01-29 2004-08-19 454 Corporation Double ended sequencing
AU2003902299A0 (en) 2003-05-13 2003-05-29 Flinders Medical Centre A method of analysing a marker nucleic acid molecule
ATE421998T1 (de) 2003-12-15 2009-02-15 Pasteur Institut Ermittlung des repertoires von b-lymphozyten populationen
EP1784646B1 (en) 2004-08-11 2012-06-13 Albert Einstein College Of Medicine Of Yeshiva University Method for identifying metastasis in motile cells
US8426146B2 (en) * 2005-06-03 2013-04-23 University of Pittsburgh—of the Commonwealth System of Higher Education Multiparameteric method for assessing immune system status
US7993821B2 (en) 2005-08-11 2011-08-09 University Of Washington Methods and apparatus for the isolation and enrichment of circulating tumor cells
US7375211B2 (en) 2005-11-18 2008-05-20 Kou Zhong C Method for detection and quantification of T-cell receptor Vβ repertoire
WO2007087312A2 (en) 2006-01-23 2007-08-02 Population Genetics Technologies Ltd. Molecular counting
CN101225441B (zh) * 2007-12-05 2010-12-01 浙江大学 一种检测克隆特异性t淋巴细胞tcr bv cdr3基因组成的方法
US11051733B2 (en) 2008-01-18 2021-07-06 Wake Forest University Health Sciences Isolating and purifying cells for therapy
EP2088205A1 (en) * 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
US20090226975A1 (en) * 2008-03-10 2009-09-10 Illumina, Inc. Constant cluster seeding
US20100137143A1 (en) 2008-10-22 2010-06-03 Ion Torrent Systems Incorporated Methods and apparatus for measuring analytes
EP2364368B1 (en) 2008-11-07 2014-01-15 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US8574835B2 (en) 2009-05-29 2013-11-05 Life Technologies Corporation Scaffolded nucleic acid polymer particles and methods of making and using
WO2011106738A2 (en) 2010-02-25 2011-09-01 Fred Hutchinson Cancer Research Center Use of tcr clonotypes as biomarkers for disease

Also Published As

Publication number Publication date
JP2013524849A (ja) 2013-06-20
WO2011139372A1 (en) 2011-11-10
JP2018068300A (ja) 2018-05-10
JP6246971B2 (ja) 2017-12-13
EP2567226B1 (en) 2016-08-10
DK2567226T3 (en) 2016-10-10
EP3144673A1 (en) 2017-03-22
DK3144673T3 (da) 2019-09-09
EP3456847B1 (en) 2024-12-25
CN103097888A (zh) 2013-05-08
CN104673899A (zh) 2015-06-03
AU2011249041A1 (en) 2012-11-22
ES2593614T3 (es) 2016-12-12
EP3456847C0 (en) 2024-12-25
EP3456847A1 (en) 2019-03-20
AU2011249041B2 (en) 2014-10-30
WO2011139371A1 (en) 2011-11-10
EP4219759A3 (en) 2023-09-06
EP3144673B1 (en) 2019-07-10
JP6158080B2 (ja) 2017-07-05
CA2798431A1 (en) 2011-11-10
ES2740802T3 (es) 2020-02-06
JP2017205112A (ja) 2017-11-24
JP6085249B2 (ja) 2017-02-22
EP2567226A1 (en) 2013-03-13
CN103097888B (zh) 2016-03-09
EP4219759A2 (en) 2023-08-02
EP2567226A4 (en) 2013-08-28
JP2013524848A (ja) 2013-06-20
JP6533272B2 (ja) 2019-06-19
SG10201503534RA (en) 2015-06-29
SG185128A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
EP4219759A3 (en) Monitoring health and disease status using clonotype profiles
Rubenstein et al. Single-cell transcriptional profiles in human skeletal muscle
Sevilla et al. Mutations in the MORC2 gene cause axonal Charcot–Marie–Tooth disease
Peeters et al. Molecular defects in the motor adaptor BICD2 cause proximal spinal muscular atrophy with autosomal-dominant inheritance
Gannon et al. Noradrenergic dysfunction in Alzheimer's disease
Satoh et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease
Gregory et al. PLA2G6-associated neurodegeneration
Fernández-Rhodes et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial
Husseiny et al. Development of a quantitative methylation-specific polymerase chain reaction method for monitoring beta cell death in type 1 diabetes
MA31753B1 (fr) Detection amelioree de l'expression de mage-a
Kumar et al. Targeted next generation sequencing in SPAST-negative hereditary spastic paraplegia
WO2011133477A3 (en) Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
HU0400904D0 (en) Use of genes as molecular markers in diagnosis of schizophrenia and diagnostic kit for the same
Souslova et al. Personalized medicine in Alzheimer's disease and depression
Ankala et al. Ancestral founder mutations in calpain‐3 in the Indian Agarwal community: Historical, clinical, and molecular perspective
Ekong et al. Variants within TSC2 exons 25 and 31 are very unlikely to cause clinically diagnosable tuberous sclerosis
Manzine et al. ADAM10 gene expression in the blood cells of Alzheimer's disease patients and mild cognitive impairment subjects
Callens et al. Real-time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: feasibility and cross-validation with NGS
CN111433608A (zh) 用于癌症诊断的肿瘤来源的外泌体的免疫应答谱分析
Liao et al. SPG35 contributes to the second common subtype of AR‐HSP in China: frequency analysis and functional characterization of FA2H gene mutations
Cope et al. Missed diagnoses: Clinically relevant lessons learned through medical mysteries solved by the Undiagnosed Diseases Network
CN101792793B (zh) miR-182作为胶质瘤发生分子标志物的应用及其检测试剂盒
Bartoli et al. Exome sequencing as a second‐tier diagnostic approach for clinically suspected dysferlinopathy patients
Barth et al. Mild cognitive impairment and Alzheimer's disease: an investigation of the CERAD-NP test battery
Jenkins et al. Shorter telomeres may indicate dementia status in older individuals with Down syndrome

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160502

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250417

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250417

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260414

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260414